Grifols Chairman Glanzmann Says CFO Alfredo Arroyo To Step Down; Role Of Grifols Chairman Will No Longer Be Executive
$GRFS
Biotechnology: Pharmaceutical Preparations
Health Care
- Bloomberg
- Bloomberg
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/12/2025 | Overweight | Morgan Stanley | |
| 3/12/2024 | Hold → Sell | Deutsche Bank | |
| 4/12/2023 | Equal-Weight → Overweight | Morgan Stanley | |
| 3/3/2023 | Overweight → Equal-Weight | Morgan Stanley | |
| 2/16/2023 | Underweight → Equal Weight | Barclays | |
| 1/18/2023 | Hold → Buy | Jefferies | |
| 4/8/2022 | Equal-Weight | Morgan Stanley | |
| 11/5/2021 | Buy → Hold | Deutsche Bank |
Believes Board Leadership Continuity and Continued Management Focus and Execution Will Drive Long-Term Shareholder Value Mason Capital Management LLC ("Mason"), a registered investment advisor to funds and accounts holding approximately 3% of Grifols S.A. ("Grifols" or the "Company") (BME: GRF) (NASDAQ:GRFS) class A shares, today announced that it sent a letter to the Grifols Board of Directors (the "Board") expressing Mason's support for the Company's recommended slate of director candidates for election at the Ordinary General Shareholders' Meeting to be held on June 4 and 5, 2025. The full text of the letter follows: May 28, 2025 Grifols, S.A. Avinguda de la Generalitat 152-158 0
‘Chronos-PD' is looking for biological signals that could indicate increased chance of developing Parkinson's disease (PD) years before symptoms appear, leading to new diagnostic tools and disease-modifying therapiesPart of broad Grifols program to find disease-revealing clues in more than 100 million proprietary plasma samples connected to real-world data on thousands of disease states in many therapeutic areasCutting-edge use of AI and proteomics technology paired with real-world evidence underscores the company's ongoing commitment to bold scientific innovation to benefit patients BARCELONA, Spain, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Grifols ((MCE: GRF, MCE: GRF.P, NASDAQ:GRFS), a global
Urges Improved Disclosure Around Key Issues for the Benefit of Grifols Shareholders Mason Capital Management LLC ("Mason"), a registered investment advisor to funds and accounts holding approximately 2.5% of Grifols S.A. ("Grifols" or the "Company") (BME: GRF) (NASDAQ:GRFS) class A shares, today sent a letter to the Spanish National Securities Market Commission (the "CNMV") calling the CNMV's attention to the troubling and value destructive lack of transparency by Grifols and its Board of Directors (the "Board"). In the letter, Mason urges the CNMV to consider the benefits to all Grifols shareholders from improved disclosure around several key issues, including: Related-party transac
Morgan Stanley resumed coverage of Grifols, S.A. with a rating of Overweight
Deutsche Bank downgraded Grifols, S.A. from Hold to Sell
Morgan Stanley upgraded Grifols, S.A. from Equal-Weight to Overweight
6-K - Grifols SA (0001438569) (Filer)
6-K - Grifols SA (0001438569) (Filer)
6-K - Grifols SA (0001438569) (Filer)